Shanghai Shen Lian Biomedical Corp (688098) - Total Assets
Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) holds total assets worth CN¥1.56 Billion CNY (≈ $228.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688098 total equity for net asset value and shareholders' equity analysis.
Shanghai Shen Lian Biomedical Corp - Total Assets Trend (2013–2024)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's total assets have evolved over time, based on quarterly financial data.
Shanghai Shen Lian Biomedical Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Shen Lian Biomedical Corp's total assets of CN¥1.56 Billion consist of 35.4% current assets and 64.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.4% |
| Accounts Receivable | CN¥264.57 Million | 17.0% |
| Inventory | CN¥95.10 Million | 6.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥135.85 Million | 8.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Shen Lian Biomedical Corp market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Shen Lian Biomedical Corp's current assets represent 35.4% of total assets in 2024, a decrease from 65.6% in 2013.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 41.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 17.0% of total assets.
Shanghai Shen Lian Biomedical Corp Competitors by Total Assets
Key competitors of Shanghai Shen Lian Biomedical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Shanghai Shen Lian Biomedical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.27 | 6.14 | 7.50 |
| Quick Ratio | 3.64 | 5.14 | 6.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥419.35 Million | CN¥486.44 Million | CN¥687.99 Million |
Shanghai Shen Lian Biomedical Corp - Advanced Valuation Insights
This section examines the relationship between Shanghai Shen Lian Biomedical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | CN¥1.55 Billion |
| Market Capitalization | $543.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Shen Lian Biomedical Corp's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai Shen Lian Biomedical Corp's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai Shen Lian Biomedical Corp (2013–2024)
The table below shows the annual total assets of Shanghai Shen Lian Biomedical Corp from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion ≈ $227.42 Million |
-2.50% |
| 2023-12-31 | CN¥1.59 Billion ≈ $233.25 Million |
-0.69% |
| 2022-12-31 | CN¥1.61 Billion ≈ $234.87 Million |
+0.41% |
| 2021-12-31 | CN¥1.60 Billion ≈ $233.91 Million |
+5.55% |
| 2020-12-31 | CN¥1.51 Billion ≈ $221.61 Million |
+4.62% |
| 2019-12-31 | CN¥1.45 Billion ≈ $211.83 Million |
+42.89% |
| 2018-12-31 | CN¥1.01 Billion ≈ $148.25 Million |
+46.36% |
| 2017-12-31 | CN¥692.19 Million ≈ $101.29 Million |
+13.89% |
| 2016-12-31 | CN¥607.79 Million ≈ $88.94 Million |
+23.96% |
| 2015-12-31 | CN¥490.32 Million ≈ $71.75 Million |
-7.29% |
| 2014-12-31 | CN¥528.89 Million ≈ $77.39 Million |
-0.50% |
| 2013-12-31 | CN¥531.53 Million ≈ $77.78 Million |
-- |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.